Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On June 14, 2017, following the resignation of Yasir B. Al-Wakeel, the former Chief
Financial Officer, Head of Corporate Development, Principal Financial Officer and Principal Accounting Officer of Merrimack Pharmaceuticals, Inc. (the Company), the Companys Board of Directors (the Board) appointed
(i) Richard Peters, the Companys President and Chief Executive Officer, to also be Principal Financial Officer and (ii) John L. Green, the Companys Controller, to also be Principal Accounting Officer.
Dr. Peters, age 54, has served as the Companys President and Chief Executive Officer and a member of its board of directors since February 2017.
Prior to joining the Company, Dr. Peters served in various capacities at Sanofi Genzyme, a global pharmaceutical company, since 2008, including as Senior Vice President, Head of Global Rare Diseases Business Unit since January 2015, Vice
President, Strategy Development Officer, U.S. Rare Disease Unit from May 2014 to December 2014, Vice President, Division Medical Officer, Global Oncology Division from 2011 to May 2014, and Vice President, Head of Global and U.S. Medical Affairs,
Hematology and Transplant from 2008 to 2011. Prior to Sanofi Genzyme, Dr. Peters held medical affairs roles at Onyx Pharmaceuticals, Inc. and Amgen Inc., both pharmaceutical companies, and was a
co-founder
and Chief Executive Officer of Mednav, Inc., a healthcare information technology company. Dr. Peters has also served on the faculty at Harvard Medical School/Massachusetts General Hospital.
Dr. Peters holds an M.D. and a Ph.D. in pharmacology from the Medical University of South Carolina and a B.S. from the College of Charleston.
Mr. Green, age 37, has served as the Companys Controller since March 2017. Prior to joining the Company, Mr. Green served as Controller at
Fractyl Laboratories, Inc., a medical technology company, from November 2015 to March 2017. From June 2014 to November 2015, Mr. Green served as Director of Accounting at Dicerna Pharmaceuticals, Inc., a biopharmaceuticals company. From
November 2013 to June 2014, Mr. Green served as a Senior Manager at Corporate Finance Group, Inc., a financial consulting firm. From 2008 to September 2013, Mr. Green served as an Assurance Manager at PricewaterhouseCoopers LLP, an
accounting firm. Prior to 2008, Mr. Green held various accounting roles at the accounting firms of Green Cumming Webber and Ernst and Young LLP. Mr. Green is a Chartered Professional Accountant and holds a B.S. from Acadia University.
There is no family relationship between Dr. Peters or Mr. Green, on the one hand, and any of the Companys directors or executive officers, on
the other hand.